PRA Health Sciences, Inc. has bought out its joint venture with Takeda Pharmaceutical Co. in Japan, which was completed on June 1. PRA Health Sciences K.K. has started its operation in Japan independently as a subsidiary of PRA.
 
With the expansion into Japan, PRA will have offices in Tokyo and Osaka, acquiring expert staff members from Takeda for the growing business. Current staff totals are 450 with the opportunity for additional growth in the near term.
 
“In recent years, clinical development that bridges simultaneous global development has become a common practice. Through the wealth of experience and expertise in advanced clinical trials in Japan acquired through the joint venture, and our strengths in clinical development across 90 countries, we strive to become an ideal drug development partner for our clients on a global scale,” said Colin Shannon, PRA President and Chief Executive Officer.
 
“The wave of new technology is present in how we conduct clinical trials. PRA is actively investing in technology, such as apps that reduce the burden on patients taking part in clinical trials, to discover new forms of clinical trials. We aim to support the clinical development work of clients to improve the lives of patients we serve,” said Atsushi Ogawa, President and Representative Director of PRA Health Sciences K.K.